STOCK TITAN

Sotera Health Company (SHC) Stock News, Aug 2025-Feb 2026

SHC NASDAQ

Sotera Health Company provides sterilization solutions, lab testing and advisory services for the healthcare industry through Sterigenics, Nordion and Nelson Labs. News about SHC commonly covers quarterly and annual operating results, constant-currency revenue trends, Adjusted EBITDA commentary and outlook updates across those businesses.

Recurring company developments also include segment performance in outsourced terminal sterilization, irradiation services and laboratory testing, as well as governance changes, board committee assignments and capital-structure activity involving its Nasdaq-listed common stock. Sterigenics uses gamma irradiation, EO processing and E-beam irradiation for medical device, pharmaceutical, food safety and other application markets.

Rhea-AI Summary

Sotera Health (Nasdaq: SHC) reported 2025 net revenues of $1.164B, up 5.7% (5.2% constant currency); net income of $78M ($0.27/diluted); Adjusted EBITDA of $594M (+8.2%); and Adjusted EPS of $0.86. This marks the 20th consecutive year of revenue growth. Balance sheet: $2.2B total debt, $345M cash, Net Leverage Ratio improved to 3.2x. 2026 outlook: net revenues $1.233–1.251B, Adjusted EBITDA $632–641M, Adjusted EPS $0.93–1.01, and capex $175–225M.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.40%
Tags
none
-
Rhea-AI Summary

Sotera Health (Nasdaq: SHC) will release fourth-quarter and full-year 2025 financial results before market open on Tuesday, February 24, 2026. Management will host a conference call at 9:00 a.m. Eastern Time the same day and provide a live webcast and replay via the company Investor Relations site.

Presentation materials and periodic updates, including information related to Ethylene Oxide, will be posted on the Sotera Health Investor Relations web pages.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
earnings date
-
Rhea-AI Summary

Sotera Health (Nasdaq: SHC) appointed Richard G. Kyle to its Board of Directors effective Feb 5, 2026. Mr. Kyle will join the Leadership Development and Compensation and Nominating and Corporate Governance committees.

He served as President and CEO of Timken from May 2014 to Sept 2024, continues on Timken’s board, and has served on Sonoco’s board since 2015. He holds a B.S. in Mechanical Engineering from Purdue and an M.B.A. from Northwestern.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
management
Rhea-AI Summary

Sotera Health (Nasdaq: SHC) is presenting at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 to update investors on its business and outlook.

Management said 2025 revenue is expected to surpass $1.16 billion, up at least 5.5% year‑over‑year (or 5.0% on a constant‑currency basis). The company reaffirmed its multi‑year revenue growth streak and announced it will release full‑year results and a 2026 outlook on February 24, 2026. A live webcast and replay of the presentation will be available on the company’s Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
none
-
Rhea-AI Summary

Sotera Health (NASDAQ: SHC) announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 1:30 p.m. ET / 10:30 a.m. PT.

Company representatives will also hold investor meetings during the conference. A live webcast and accompanying materials will be posted on the company's Investor Relations website, and a replay will be available within 48 hours and remain archived on the site.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
none
-
Rhea-AI Summary

Sotera Health (Nasdaq: SHC) announced a secondary offering of 30,000,000 shares of common stock on November 6, 2025.

All shares are being sold by affiliates of Warburg Pincus and GTCR; the company is not selling shares and will not receive proceeds. Goldman Sachs is the underwriter. The company will pay offering expenses under its registration rights agreement. A registration statement filed with the SEC on February 27, 2024 became effective automatically. The offering is made only by prospectus and is not an offer in jurisdictions where unlawful.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
Rhea-AI Summary

Sotera Health (Nasdaq: SHC) reported Q3 2025 net revenues of $311M, up 9.1% (8.0% constant currency), net income of $48M ($0.17 diluted) and Adjusted EBITDA $164M, up 12.2% (11.2% cc).

Year-to-date net revenues were $860M (+6.2%), Adjusted EBITDA $437M (+10.4%), and Adjusted EPS $0.60. The company raised its 2025 Adjusted EBITDA growth outlook to 6.75%-7.75%, reaffirmed revenue growth of 4.5%-6.0% (cc), and lowered 2025 capex to $125M-$135M. Balance sheet highlights: $2.2B total debt, $299M unrestricted cash, and Net Leverage at 3.3x.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
none
-
Rhea-AI Summary

Sotera Health (Nasdaq: SHC) will release third-quarter 2025 financial results for the period ended September 30, 2025 before the market opens on Tuesday, November 4, 2025.

Management will host a conference call at 9:00 a.m. Eastern Daylight Time the same day to discuss results and operating highlights. Participants may dial 1-844-481-2916 (U.S. toll-free) or 1-412-317-0709 from other locations. A live webcast and accompanying materials will be available via the company’s Investor Relations Presentation & Events page, and a replay of the webcast will be posted later on November 4.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
-
Rhea-AI Summary

Sotera Health (Nasdaq: SHC) has announced a secondary offering of 20 million shares of its common stock. The offering is being conducted by selling stockholders affiliated with Warburg Pincus and GTCR, with Goldman Sachs & Co. LLC serving as the underwriter.

The company itself is not selling any shares and will not receive any proceeds from the offering, although it will cover the offering expenses per its Amended and Restated Registration Rights Agreement. The offering will be made through a prospectus, with a registration statement already filed and effective with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.00%
Tags
Rhea-AI Summary

Sotera Health (NASDAQ:SHC) reported strong Q2 2025 results with net revenues increasing 6.4% to $294 million. The company posted net income of $8 million ($0.03 per diluted share) and Adjusted EBITDA grew 9.8% to $151 million.

Key segment performance includes Sterigenics' revenue growth of 10.5% to $195 million, Nordion's increase of 2.9% to $42 million, while Nelson Labs saw a decline of 3.3% to $57 million. The company raised its full-year 2025 outlook, now expecting net revenue growth of 4.5% - 6.0% and Adjusted EBITDA growth of 6.0% - 7.5% on a constant currency basis.

The company maintains a strong balance sheet with $2.3 billion in total debt and $332 million in unrestricted cash, with an improved Net Leverage Ratio of 3.5x.

[ "Q2 net revenues increased 6.4% to $294 million", "Adjusted EBITDA grew 9.8% to $151 million with 160 basis points margin expansion", "Sterigenics segment showed strong 10.5% revenue growth to $195 million", "Company raised full-year 2025 outlook for revenue and Adjusted EBITDA", "Net Leverage Ratio improved to 3.5x from 3.7x", "No balance outstanding on $600 million revolving credit facility" ]
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.51%
Tags
none

FAQ

What is the current stock price of Sotera Health (SHC)?

Sotera Health (SHC) last closed at $16.61.

What is the market cap of Sotera Health (SHC)?

The market cap of Sotera Health (SHC) is approximately $4.7B.